Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment

Androgen receptor (AR) antagonists, such as enzalutamide, have had a major impact on the treatment of metastatic castration-resistant prostate cancer (CRPC). However, even with the advent of AR antagonist therapies, patients continue to develop resistance, and new strategies to combat continued AR s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neoplasia
Main Authors: Kregel, Steven, Wang, Chao, Han, Xin, Xiao, Lanbo, Fernandez-Salas, Ester, Bawa, Pushpinder, McCollum, Brooke L., Wilder-Romans, Kari, Apel, Ingrid J., Cao, Xuhong, Speers, Corey, Wang, Shaomeng, Chinnaiyan, Arul M.
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2020
Assuntos:
Original article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6957805/
https://ncbi.nlm.nih.gov/pubmed/31931431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2019.12.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados